The newly established Journal of Urologic Oncology (JUO), which succeeded the Korean Journal of Urologic Oncology, which was founded in 2003 as the official journal of the Korean Urologic Oncology Society, is celebrating its second year of publication with a complete English translation in 2023.Over the past year, JUO has published timely reviews of emerging research trends in the fields of prostate, kidney, and bladder cancer by world-renowned experts in the field, as well as topical feature articles on the most updated topics in urological oncology, which it claims have helped to keep readers abreast of the latest treatment trends.This year's JUO will further mature last year's experimental attempts in content and format to become a journal that meets our goal of becoming an SCIE-rated journal.First, from this issue 4, we have introduced reporting guidelines to help readers understand the title and format.We have adopted the CONSORT guideline for randomized clinical trials, the RPISMA statement for systemic reviews, and the STROBE guideline for observational studies, and we will continue to strive to ensure that these policies are reflected in the submission and revision of articles.Regarding quality, we aim to be a multinational journal by allowing researchers worldwide to submit original articles and review articles on significant treatment trends.In the March issue of JUO in 2024, we have 2 systemic reviews and 3 invited reviews on each cancer type from world-leading researchers.
No takes yet. Share an insight, caveat, or question.
Cheol Kwak (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: